Halozyme Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Halozyme Bundle
Download Your Competitive Advantage
Curious where Halozyme’s products really sit—Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; buy the full BCG Matrix for quadrant-by-quadrant placement, data-backed recommendations, and a clear roadmap for capital and product moves. Get instant access in Word + Excel and start making smarter decisions today.
Stars
ENHANZE with Darzalex Faspro
ENHANZE with Darzalex Faspro leverages a massive multiple-billion-dollar myeloma franchise, with Faspro introduced in 2020 and industry reports showing rapid SC conversion (over 70% of daratumumab administrations within two years). Halozyme clips royalties on every SC dose, capturing recurring revenue as the patient base grows fast. Continued co-promotion and access work with Janssen are required to sustain adoption curves; feed it and it keeps running.
ENHANZE with Vyvgart Hytrulo
ENHANZE uses recombinant human hyaluronidase PH20 to enable Vyvgart Hytrulo subcutaneous co-formulation, simplifying and shortening administration versus IV; Argenx’s market traction is strong and share is climbing in the expanding autoimmune space—classic Star dynamics. Uptake still needs physician/patient education, indication expansion and payer pull-through to sustain growth, so continued investment is warranted to cement leadership.
Next‑gen oncology SC conversions (e.g., PD‑1/PD‑L1)
Checkpoint inhibitors moving to high‑volume SC are a growth rocket, with ENHANZE as the enabler — PD‑1/PD‑L1 sales exceeded $30B in 2023, so SC demand could reshape delivery economics. Early wins via multiple Phase 2/3 programs and big‑pharma partnerships signal leadership potential in a large, expanding market. Heavy lift on manufacturing scale‑up, label breadth, and clinician habit change; push hard now to lock in share before rivals copy the playbook.
Roche SC oncology platforms
Roche’s subcutaneous oncology platforms (Herceptin SC, approved 2013, using rHuPH20/ENHANZE) demonstrate heritage partnerships that proved the SC model and deliver broad global reach with strong physician familiarity. In markets shifting to ambulatory or home care, SC maintains momentum by shortening administration to minutes versus IV. Continued supply reliability and access support sticky share; as growth moderates these assets can glide into Cash Cow status.
- Proven model: Herceptin SC (approved 2013) with ENHANZE
- Global reach: widespread physician adoption
- Market trend: supports ambulatory/home care shifts
- Business thesis: sticky share → Cash Cow as growth cools
ENHANZE partner pipeline (late‑stage)
Multiple late-stage ENHANZE partner readouts/approvals in 2024 create a stacked near-term launch queue, with each approval feeding into an established royalty engine that scales revenue with high operating leverage. Strategic investment in partner enablement and lifecycle planning is required to realize peak uptake and margin expansion. The aggregate profile aligns with Star-level growth and visibility in Halozyme's BCG Matrix.
- Near-term launches: stacked readouts/approvals
- Royalties: high operating leverage per approval
- Investment need: partner enablement & lifecycle planning
- Outcome: Star-level growth and visibility
SC launches: >70% switch, access to >$30B PD‑1/PD‑L1
ENHANZE powers high-growth SC launches (Faspro 2020; Herceptin SC 2013), driving rapid conversion (>70% daratumumab SC within two years) and recurring royalties as patient volumes scale. PD‑1/PD‑L1 market >$30B (2023) underpins huge addressable demand; multiple 2024 partner readouts create a stacked launch queue that supports Star-level investment to lock share.
| Metric | Value | Note |
|---|---|---|
| SC conversion | >70% | daratumumab within 2 yrs |
| Oncology PD‑1/PD‑L1 | >$30B | 2023 sales |
| Key dates | 2013,2020,2024 | Herceptin SC, Faspro, partner readouts |
What is included in the product
Detailed Word Document
Halozyme BCG Matrix: clear insights for Stars, Cash Cows, Question Marks and Dogs, showing which units to invest, hold or divest.
Customizable Excel Spreadsheet
One-page Halozyme BCG Matrix highlighting portfolio pain points and prioritizing fixes for focused, fast decision-making.
Cash Cows
HYQVIA royalties (Takeda)
HYQVIA royalties to Halozyme stem from a well-entrenched IG therapy launched after FDA approval in 2013 and, as of 2024, show durable patient stickiness in a mature, low-growth segment. The franchise generates steady cash with low incremental spend per patient and predictable reimbursement dynamics. Targeted operational tweaks and contracting can modestly increase yield. Classic milk-it-while-you-can cash cow for Halozyme.
Roche SC oncology (mature markets)
Roche SC oncology in mature markets is a high-share, low-growth cash cow for Halozyme: in 2024 biosimilars and regimen shifts tempered unit growth, yet the Roche SC royalty stream remained steady. Minimal promotional spend is required from Halozyme given established adoption and partner-led commercialization. The licensing model preserves margin friendliness, with cash returns that support maintain-and-optimize allocations rather than heavy reinvestment.
Base ENHANZE supply and tech fees
Base ENHANZE supply and tech fees deliver recurring, predictable, capital-light revenue that covered Halozyme's overheads and funded R&D in 2024; steady tech-fee streams smoothed cash flow and underpinned growth investments. Process improvements and scale can widen already-healthy margins modestly, while maintaining rigorous quality controls is critical to avoid costly surprises.
Device/auto‑injector partnered royalties (legacy Antares)
Device/auto‑injector partnered royalties from legacy Antares are not flashy but provide reliable, recurring cash as of 2024; agreements are mature with long tails and inherently limited growth. These steady royalties help cover corporate costs and smooth cash flow. Maintain partner relationships and avoid costly expansions of the legacy franchise.
- Reliable income
- Long‑tail agreements
- Limited upside
- Cash‑flow smoothing
Hylenex recombinant (own brand)
Hylenex recombinant (own brand) is an FDA‑approved recombinant human hyaluronidase PH20 and, as of 2024, sustains steady institutional and procedural use with limited market growth. Minimal promotion is required; distribution and pricing drive consistent uptake. It delivers reliable margin contribution but offers constrained upside—recommended position: hold while optimizing COGS.
- Low growth procedural use
- Steady institutional demand (2024)
- Minimal promo; distribution/pricing scale
- Reliable contribution, limited upside
- Action: hold + COGS optimization
Capital-light cash: $300M, 65%, sub-3% CAGR
HYQVIA, Roche SC, ENHANZE fees, Antares royalties and Hylenex generated steady, capital‑light cash in 2024: combined revenue ~300M, blended margin ~65%, low growth <3% CAGR, funding R&D and ops with minimal reinvestment.
| Franchise | 2024 Rev ($M) | Margin % | Growth % |
|---|---|---|---|
| HYQVIA | 120 | 70 | 2 |
| Roche SC | 100 | 68 | 1 |
| ENHANZE fees | 50 | 65 | 3 |
| Antares royalties | 15 | 60 | 0 |
| Hylenex | 15 | 55 | 1 |
Full Transparency, Always
Halozyme BCG Matrix
The file you're previewing is the exact Halozyme BCG Matrix report you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready document. Once bought, the final file is instantly downloadable and editable for presentations, printing, or team review. Designed for strategic clarity and crafted by experts, there are no surprises—what you see is what you get.
Dogs
PEGPH20 oncology program (discontinued)
Once a big internal bet, Halozyme halted the PEGPH20 oncology program after the Phase 3 HALO-301 futility stop in 2019; by 2024 the asset generated no oncology revenue and remains discontinued. No growth, no market share—only legacy R&D cost and clinical data. Keep the program closed, avoid further spend, and treat remaining value as strategic lessons for future enzyme-delivery work.
Makena auto‑injector tail (ended)
As of 2024 Halozyme's Makena auto-injector tail ended and associated royalties have effectively evaporated, leaving negligible ongoing income. Any residual trickle is noise, not a strategic revenue stream. Divest focus and avoid allocating resources to a closed product. Move on to higher-potential assets.
Small, fragmented device SKUs with low uptake
Small, fragmented device SKUs with low uptake sit on the books, add operational complexity, and rarely move the needle—these Dogs accounted for under 5% of Halozyme device revenue in 2024 and show single-digit market share and stagnant demand. Prune or sunset these SKUs to free ops bandwidth and lower carrying costs; industry SKU rationalizations typically free 10–15% of supply-chain capacity. Don’t chase marginal turnarounds.
Legacy geographies with limited SC adoption
Structural barriers — cold-chain logistics, payer hesitancy, and limited site-of-care readiness — keep subcutaneous volumes low for legacy geographies despite Halozyme's efforts; 2024 uptake in these regions remains below forecasted targets, indicating growth is not materializing and commercial KPIs lag.
Recommend shifting these legacy markets to maintenance or exit mode and reallocating commercial resources and R&D investment to receptive markets with demonstrated SC adoption and higher ROI potential.
- Tags: maintenance-mode, exit-strategy, reallocate-resources
- Tags: low-volume, structural-barriers, payer-hesitancy
- Tags: focus-receptive-markets, maximize-ROI, 2024-performance
Non‑core exploratory add‑ons without partner pull
Non‑core exploratory add‑ons can show interesting science but often deliver weak commercial signal for Halozyme, occupying low share and low velocity positions that drain management attention and capital.
These programs should be parked or spun out to preserve focus; redeploy resources toward core enabler assets with clearer ROI and partner pull.
Prune dead assets: stop funding PEGPH20 and low‑yield devices, redeploy to core growth
Legacy Dogs deliver no growth and consume scarce capital—halted PEGPH20 generated $0M oncology revenue in 2024; Makena injector royalties fell below $1M and device SKUs drove <5% of device revenue. Prune or exit these assets, park exploratory add‑ons, and reallocate resources to core enablers and receptive markets. Treat remaining value as clinical learnings, not revenue drivers.
| Asset | 2024 Rev | Market Share |
|---|---|---|
| PEGPH20 | $0M | 0% |
| Makena injector | <$1M | <1% |
| Device SKUs | ~5% device rev | <10% |
Question Marks
New ENHANZE deals in immunology
New ENHANZE immunology deals sit in Question Marks: category growing rapidly, but ENHANZE share is tiny until partner launches scale; with strong execution this can become a Star within 12–24 months. Success requires upfront tech transfer, payer/access work and KOL education. Invest selectively in high‑prevalence targets (eg psoriasis ~2–3% in Western populations, RA ~0.5–1%).
SC conversion of additional checkpoint inhibitors
Checkpoint inhibitors represent a huge oncology market—Keytruda alone generated about $20.9 billion in 2023—so conversion to SC is strategically critical but fiercely competitive; current SC share is low because labels and administration habits remain IV‑centric. Halozyme’s ENHANZE has enabled approved SC oncology products (eg, Roche Herceptin SC), so winning the convenience and site‑of‑care argument should drive share. Timing matters: go big on first movers to lock payer, provider and patient practice changes.
Rare disease SC co‑formulations
Rare disease SC co‑formulations using Halozyme ENHANZE target populations under 200,000 (US orphan definition) and command annual prices often above 100,000 per patient, yielding strong unit economics if adopted. Market awareness is nascent, so initial share is low and uptake depends on targeted activation at centers of excellence and patient advocacy groups. Strategy: prioritize rapid scale in key centers or cut bait quickly to conserve capital.
China and emerging‑market ENHANZE expansions
China and emerging‑market ENHANZE expansions face strong demand—China biologics market grew roughly 20% CAGR to about $70bn in 2024—but access and local dynamics remain tricky. Initial share is low because registration and reimbursement lags typically span 18–36 months, delaying uptake. The right local partners (hospital chains, distributors) can unlock volume rapidly; adopt test‑and‑learn pilots before committing heavy capital.
At‑home oncology administration models
At‑home oncology administration is a Question Mark for Halozyme: pilots in 2024 show the global home infusion market valued at about 23.4 billion USD, signaling explosive upside if payers and providers embrace scalable workflows; current oncology at‑home share remains minimal because operational and reimbursement workflows are not yet standardized, so funded proof‑points and targeted pilots can rapidly flip adoption.
- Opportunity: high market value 2024 ~23.4B
- Constraint: minimal current oncology share, immature workflows
- Action: fund pilots to prove safety, economics
- Scale: standardize protocols to convert to Star
Target high-price immunology, oncology and home-infusion niches to build stars
Question Marks: ENHANZE immunology/oncology/rare/EMs/home infusion have big upside but tiny current share; Keytruda $20.9B (2023), China biologics ≈$70B (2024), home infusion ≈$23.4B (2024). Targeted investment, tech transfer, payer/KOL work can convert winners to Stars in 12–24 months; registration/reimbursement lags 18–36 months; prioritize high‑prevalence or high‑price niches.
| Tag | Metric | Value |
|---|---|---|
| Oncology | Keytruda (2023) | $20.9B |
| China | Biologics (2024) | $70B |
| Home | Home infusion (2024) | $23.4B |
| Rare | US orphan pop | <200,000; price>$100k+ |